Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | CCR2 | P41597 | 7/20 | 0.45 |
| ▸ | KCNH2 | Q12809 | 6/20 | 0.44 |
| ▸ | CACNA1G | O43497 | 2/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | PPARG | P37231 | 1/20 | 0.43 |
| ▸ | USP2 | O75604 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3033580 | 0.95 | CCR2 (0.43) | CYP2D6TSHRCCR2KCNH2CACNA1G | |
| SCHEMBL3042078 | 0.93 | TSHR (0.46) | CYP2D6TSHRCCR2KCNH2CACNA1G | |
| SCHEMBL3034310 | 0.93 | KMT2A (0.48) | CYP2D6TSHRCCR2KCNH2CACNA1G | |
| SCHEMBL3038231 | 0.88 | GAA (0.49) | CYP2D6TSHRCCR2KCNH2CACNA1G | |
| SCHEMBL13222917 | 0.88 | CCR2 (0.47) | CYP2D6TSHRCCR2KCNH2CYP3A4 | |
| SCHEMBL3041001 | 0.86 | CCR2 (0.43) | CCR2KCNH2CYP3A4 | |
| SCHEMBL3039081 | 0.86 | CCR2 (0.47) | CYP2D6TSHRCCR2KCNH2CACNA1G | |
| SCHEMBL3035011 | 0.86 | CYP2D6 (0.46) | CYP2D6TSHRCCR2KCNH2CACNA1G | |
| SCHEMBL3039263 | 0.86 | CCR2 (0.45) | CYP2D6TSHRCCR2KCNH2CACNA1G | |
| SCHEMBL3023504 | 0.85 | CCR2 (0.47) | CYP2D6TSHRCCR2KCNH2PPARG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100210633-A1 | CARBOXAMIDE COMPOUNDS AND THEIR USE | EPIX DELAWARE, INC. (US) | 2010-08-19 | — | — | US | claimed |
| US-20100210633-A1 | CARBOXAMIDE COMPOUNDS AND THEIR USE | EPIX DELAWARE, INC. (US) | 2010-08-19 | — | — | US | disclosed |
| US-20100210633-A1 | CARBOXAMIDE COMPOUNDS AND THEIR USE | EPIX DELAWARE, INC. (US) | 2010-08-19 | — | — | US | disclosed |
| WO-2008045564-A2 | CARBOXAMIDE COMPOUNDS AND THEIR USE AS ANTAGONISTS OF THE CHEMOKINE CCR2 RECEPTOR | EPIX DELAWARE, INC. (US) | 2008-04-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100210633-A1 | CARBOXAMIDE COMPOUNDS AND THEIR USE | CCR2, CCR1, CCR5 | CYP2D6 1241/4885TSHR 1158/4885CCR2 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.